Histopathological manifestations of membranoproliferative glomerulonephritis and glomerular expression of plasmalemmal vesicle-associated protein-1 in a patient with polycythemia vera.
Only a few cases of various glomerulonephropathies have been reported in patients with polycythemia vera. We report the case of a 72-year-old female with polycythemia vera in whom renal biopsy examination showed membranoproliferative glomerulonephritis (MPGN)-like lesion and glomerular expression of plasmalemmal vesicle-associated protein-1 (PV-1), a marker of glomerular capillary remodeling after injury. Prior to admission to our hospital for nephrotic syndrome, she had received hydroxyurea and phlebotomy. On admission, she was hypertensive with pretibial edema, hepatosplenomegaly, massive proteinuria (6.14 g/day), low serum albumin (2.9 g/dl), high fibrinogen, fibrin/fibrinogen degradation products and thrombomodulin levels, but with normal serum creatinine and complement levels. Microscopic examination of a renal biopsy demonstrated MPGN-like features with double contour and mesangial interposition. Electron microscopy showed subendothelial deposits, platelets attached to glomerular capillary walls and fibrin deposition. Immunofluorescence study identified IgM deposition along part of the capillary wall and mesangium. CD42b-positive platelets and megakaryocytes were detected in glomerular capillaries, accompanied with increased expression of platelet-derived growth factor receptor b and thrombomodulin in the mesangium and glomerular capillary, respectively. PV-1 was expressed along the glomerular capillary. Anti-platelet and anticoagulant combination therapy, together with the use of anti-hypertensive agents and hydroxyurea, resulted in improvement of the nephrotic syndrome. The findings suggested that activated platelets, enhanced coagulation state and endothelial damage may contribute to glomerulonephropathy associated with polycythemia vera.
Nishi
Y
Y
Divisions of Nephrology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.
Namikoshi
T
T
Sasaki
T
T
Tokura
T
T
Nagasu
H
H
Nakanishi
H
H
Kozuka
Y
Y
Kashihara
N
N
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001706:Biopsy; D002352:Carrier Proteins / Q000032:analysis*; D004359:Drug Therapy, Combination; D005260:Female; D005455:Fluorescent Antibody Technique; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007678:Kidney Glomerulus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008565:Membrane Proteins / Q000032:analysis*; D008854:Microscopy, Electron; D009404:Nephrotic Syndrome / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
D000925:Anticoagulants; D000959:Antihypertensive Agents; D002352:Carrier Proteins; D008565:Membrane Proteins; C486771:PLVAP protein, human; D010975:Platelet Aggregation Inhibitors; D006918:Hydroxyurea